Acute Respiratory Distress Syndrome (ARDS) Clinical Trials

Find Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Near You

Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Patients With Traumatic Brain Injury: The Prospective, Observational, Multi-center FARDS Study

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

this study aims to assess the ability of fibrinogen-to-albumin ratio to predict the development of Acute respiratory distress syndrome in traumatic brain injury patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients ≥ 18 years admitted to the ICU with traumatic Brain Injury

• Admission to the ICU within 24 hours of injury.

• Patients will be expected to remain under hospital care for follow-up

• Availability of fibrinogen and albumin measurements within the first 24 hours of ICU admission.

• Informed consent will be obtained from a legally authorized representative.

Locations
Other Locations
Egypt
Tanta University Hospitals
RECRUITING
Tanta
Contact Information
Primary
Eman M Taher, MD
emantaher6669@gmail.com
01090822808
Time Frame
Start Date: 2026-07-01
Estimated Completion Date: 2027-01-01
Participants
Target number of participants: 350
Treatments
Acute respiratory distress syndrome group
patients who will develop ARDS within 7 days of ICU admission, defined according to the Berlin criteria. Fibrinogen (g/L) and albumin (g/L) levels in the blood will be measured from the first routine blood sample after ICU admission.~Fibrinogen-to-albumin ratio will be calculated as:~FAR = Fibrinogen (g/L)/Albumin (g/L)
Non acute respiratory distress syndrome group
patients who will not develop ARDS within 7 days of ICU admission. Fibrinogen (g/L) and albumin (g/L) levels in the blood will be measured from the first routine blood sample after ICU admission.~Fibrinogen-to-albumin ratio will be calculated as:~FAR = Fibrinogen (g/L)/Albumin (g/L)
Sponsors
Leads: Tanta University

This content was sourced from clinicaltrials.gov